Optimizing Lipid-Lowering Strategies Beyond Current Evidence.

This letter addresses the recent study by Sohn et al., which compared moderate-intensity atorvastatin plus ezetimibe with high-intensity atorvastatin in patients with angina undergoing PCI. We emphasize key limitations, including the absence of LDL-C values, potential residual confounding, and the small CKD subgroup sample size. Furthermore, adherence and safety outcomes were not adequately assessed. While the study supports non-inferiority of combination therapy, further prospective research is needed to clarify optimal lipid-lowering strategies in this high-risk population.